Peter Kiener - Nov 15, 2021 Form 4 Insider Report for Cue Biopharma, Inc. (CUE)

Role
Director
Signature
/s/ Peter Kiener by Colin Sandercock, attorney-in-fact
Stock symbol
CUE
Transactions as of
Nov 15, 2021
Transactions value $
-$303,987
Form type
4
Date filed
11/17/2021, 04:00 PM
Previous filing
Jun 29, 2021
Next filing
Jan 5, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CUE Common Stock Options Exercise $53.8K +18.8K $2.86 18.8K Nov 15, 2021 Direct F1
transaction CUE Common Stock Sale -$337K -18.8K -100% $17.92 0 Nov 15, 2021 Direct F1, F2
transaction CUE Common Stock Options Exercise $3.89K +1.36K $2.86 1.36K Nov 16, 2021 Direct F1
transaction CUE Common Stock Sale -$24.5K -1.36K -100% $18.02 0 Nov 16, 2021 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CUE Stock Option (right to buy) Options Exercise $0 -18.8K -14.94% $0.00 107K Nov 15, 2021 Common Stock 18.8K $2.86 Direct F1, F4
transaction CUE Stock Option (right to buy) Options Exercise $0 -1.36K -1.27% $0.00 106K Nov 16, 2021 Common Stock 1.36K $2.86 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 18, 2020.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.86 to $18.20, inclusive. The reporting person undertakes to provide to Cue Biopharma, Inc., any security holder of Cue Biopharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.86 to $18.31, inclusive. The reporting person undertakes to provide to Cue Biopharma, Inc., any security holder of Cue Biopharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (3) to this Form 4.
F4 The option vests in five equal annual installments beginning March 23, 2017.